Access Resources and Additional Information About KENGREAL® (cangrelor)

Chiesi provides KENGREAL materials and information to help your practice. Choose the option below that best fits your needs.

I’m looking for…
Downloadable resources
KENGREAL® (cangrelor) reimbursement guide Reimbursement Guide Download PDF
KENGREAL dosing and administration guide Dosing & Administration Guide Download PDF
KENGREAL order sheet Order Sheet Download PDF
KENGREAL sell sheet Sell Sheet Download PDF
Contact from a KENGREAL representative, a Dosing Lanyard, and/or a Dosing Door Hanger
Please complete the form below:










Terms and Conditions

By checking this box, you are giving Chiesi USA, Inc. permission to send or contact you with the information you have requested, as well as information and updates on KENGREAL® (cangrelor) or other Chiesi products in the future. Chiesi USA, Inc. will not sell or share any of your information with third parties.

Email updates about KENGREAL
Please complete the form below:





Terms and Conditions

By checking this box, you are giving Chiesi USA, Inc. permission to send or contact you with the information you have requested, as well as information and updates on KENGREAL® (cangrelor) or other Chiesi products in the future. Chiesi USA, Inc. will not sell or share any of your information with third parties.

Medical Information

To request specific medical information about KENGREAL or to report adverse events or product complaints, contact the Medical Information Department.

Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088.


Mail:
Chiesi USA, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518


Phone:
1-888-661-9260


Fax:
1-866-443-3092


Email:
US.Medical@chiesi.com

Contact Chiesi USA, Inc.

Mail:
Chiesi USA, Inc.
1255 Crescent Green Drive
Suite 250
Cary, NC 27518


Phone:
1-888-466-6505

IMPORTANT SAFETY INFORMATION

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

INDICATION

KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.